
CM Revanth Reddy, Union Minister Piyush Goyal to participate in BioAsia 2025
The Hindu
BioAsia 2025: Leading industry luminaries and global leaders gather towards making India a leader in Life Sciences sector.
Telangana Chief Minister A. Revanth Reddy, Union Commerce and Industry Minister Piyush Goyal, G20 Sherpa Amitabh Kant and Governor of Queensland Jeannette Young, besides global leaders and top executives, are scheduled to participate in BioAsia 2025, the next in the annual series of conference focused on the Life Sciences sector that Hyderabad will be hosting on February 25 and 26.
It boasts of a line-up of inspirational speakers and industry luminaries in discussion with participating leaders, MSME’s and startups towards making India an undisputed leader in the Life Sciences space. BioAsia 2025 is all set to act as a ‘Catalyst of Change’, the organisers said in a release on Thursday.
Notable industry leaders who will attend BioAsia include Chairman and CEO of Amgen Robert A. Bradway, executive director, Genome Institute of Singapore Patrick Tan, Medtronic CTO Ken Washington, Miltenyi Biotec managing director Boris Stoffel.
The CEO conclave scheduled on February 25 will have as speakers - former chairman of ISRO S. Somanath, Dr. Reddy’s Laboratories chairman Satish Reddy, Bharat Biotech founder and CMD Krishna Ella, Laurus Labs founder and CEO Satyanarayana Chava; Chief Commercial Officer, APMA region of Novartis Cesar Concepcion and president and general manager of Lilly India Winselow Tucker. They will be discussing the key opportunities and challenges for the life sciences in Indian and overseas markets.
Industries and IT Minister D. Sridhar Babu said “BioAsia 2025 marks the 22nd edition of Asia’s leading life sciences and healthcare forum. It brings together global leaders to discuss AI-driven healthcare transformation, innovations in life sciences, data interoperability, and India’s potential in clinical trials...”